Measles Outbreak in Australia: What doctors should do?

Australia was declared measles-free in 2014. But “eliminated” does not mean “eradicated.” The virus is just a plane ride away.

In 2025, Australia recorded 180 measles cases – more than triple the 57 cases reported in 2024 . And the numbers for 2026 are already climbing, with recent outbreaks in Western Australia, Queensland, New South Wales, and Victoria .

For doctors on the front lines, this is not just a public health issue. It is a clinical reality. Patients with fever and rash are appearing in GP waiting rooms and emergency departments across the country. Some have travelled overseas. Some have not. And every missed diagnosis is a potential super-spreader event.

This article provides a practical, evidence-based guide for Australian doctors responding to the current measles outbreak in Australia. You will learn how to recognise a typical presentations, fulfill statutory notification duties, implement infection control, administer post-exposure prophylaxis, and close immunity gaps in your patient population.

Why Measles Is Back: The 2026 Context

The Global Driver

Measles remains endemic in many popular travel destinations. Current outbreaks are active in:

Indonesia (including Bali)
Vietnam
Thailand and surrounding countries
New Zealand
The United Kingdom
The United States and Canada

Fully vaccinated individuals are protected. But under-vaccinated travellers risk both contracting measles and spreading the virus upon returning to Australia . This is precisely what is happening.

The Australian Picture

As of early 2026, multiple jurisdictions have issued public health alerts:

State/Territory	Recent Activity
NSW	27 cases (Dec 2025 – Feb 2026); locally acquired cases with unknown source; GP waiting room exposures documented
WA	Ongoing outbreak activity
QLD	Multiple cases reported in 2026
VIC	Imported cases and local transmission in western suburbs

Most cases have occurred in under-vaccinated adults, not young children . This is a critical shift from traditional measles epidemiology and has significant implications for clinical practice.

Recognising Measles: Clinical Features and Diagnostic Challenges

Classic Presentation

After an incubation period of 7–18 days (average 10 days) , measles typically presents with :

Prodromal phase (2–4 days):

Fever (often >40°C)
The “3 Cs”: Cough, Coryza (runny nose), Conjunctivitis (red, watery eyes)
Koplik spots – small white spots on the buccal mucosa (pathognomonic but often missed)

Rash phase:

Begins at the hairline and spreads downward to the face, trunk, and extremities
Maculopapular (red, blotchy)
May become confluent on the face and upper trunk
Appears approximately 14 days after exposure

Atypical Presentations in Vaccinated Individuals

This is crucial. Previously vaccinated individuals may present with milder, atypical symptoms . The classic rash may be muted or absent. Fever may be lower. This creates a high risk of missed diagnosis.

Always consider measles in any patient with:

Fever and rash, regardless of vaccination status
Unexplained febrile illness with travel history
Contact with a known measles case or attendance at a public exposure site

The Travel History Question

Ask every patient with fever and rash:

Have you travelled overseas in the past three weeks?
Have you been in contact with anyone who has travelled overseas?
Have you visited any of the public exposure locations listed on state health department websites?

Red flag: Measles is now circulating locally. An absence of travel history does not exclude measles .

Immediate Actions: What To Do When You Suspect Measles

The window for effective public health intervention is measured in hours, not days. Follow this protocol immediately upon suspicion.

Step 1: Isolate – Immediately

Measles is one of the most contagious infectious diseases known. Transmission occurs via airborne and respiratory droplets to anyone sharing the same airspace . The virus remains infectious in the air for up to two hours after an infected person has left the room.

Action:

Place the patient in a single room with airborne precautions
Keep the room vacant for 30 minutes after the patient departs
If a single room is unavailable, do not place the patient in a crowded waiting room. Consider outdoor triage or a dedicated isolation area
Provide a surgical mask for the patient to wear

Step 2: Notify – Urgently (Statutory Requirement)

Measles is a Group A notifiable disease in every Australian jurisdiction . This means:

Notification is required by telephone to the local Public Health Unit (PHU) within a few hours of first suspicion – even before laboratory confirmation
Do not wait for test results

National PHU Contact Number: 1300 066 055

When calling, be prepared to provide:

Patient demographics and contact details
Date of symptom onset
Travel history
Vaccination status
Locations visited while infectious (including your own waiting room)

Step 3: Test – Correct Specimen Collection

Preferred specimens for PCR (gold standard):

Throat swab (dry or in universal transport medium)
First-pass urine (at least 10-20 mL)

Serology:

Collect blood for measles IgG and IgM
Important: Serology alone is insufficient for diagnosis. IgM may be negative early in the illness. PCR is required.

Practical tips:

Mark all tests as “URGENT – SUSPECTED MEASLES” on the request form
Note travel history or known exposure on the form
Contact the laboratory to confirm they will expedite processing
If testing for other respiratory pathogens, use a separate swab so measles PCR is not delayed

Step 4: Manage – According to Clinical Status

If the patient is clinically well:

Advise home isolation until test results are available AND until 4 days after rash onset
Provide clear written instructions on isolation and symptom monitoring
Arrange for results to be communicated urgently

If the patient requires hospitalisation:

Telephone the hospital before transfer so infection control measures can be in place upon arrival
Advise ambulance personnel of the suspected diagnosis

Post-Exposure Prophylaxis (PEP): A Time-Critical Intervention

When a susceptible person is exposed to measles, there is a narrow window to prevent infection or modify disease severity. The local Public Health Unit will determine who qualifies for PEP and which product to use .

Two PEP Options

Feature	MMR Vaccine	Normal Human Immunoglobulin (NHIG)
Time window	Within 72 hours of first exposure	Within 144 hours (6 days) of exposure
Mechanism	Live attenuated virus – induces active immunity	Passive antibodies – immediate but temporary protection
Route	Intramuscular injection	Intramuscular injection
Indications	• Age ≥6 months • Immunocompetent • Not pregnant	• Age <6 months • Pregnancy • Immunocompromised • Exposure 73-144 hours post-exposure

Important Nuances

MMR vaccine within 72 hours can prevent measles entirely in susceptible contacts.

NHIG within 144 hours may not prevent infection but will modify or attenuate the disease . NHIG is a fractionated blood product made from pooled human plasma . It is:

Available only under the direction of a PHU
Ordered through the National Blood Authority (not standard pharmaceutical wholesalers)
Provided at no cost to eligible patients

For infants aged 6–11 months who receive MMR as PEP: This dose counts as an early additional dose. They will still need two further doses – at 12 months (or 4 weeks after the first dose, whichever is later) and at 18 months (as MMRV) .

If a Patient Requests PEP Without PHU Referral

Do not administer PEP without PHU guidance. Contact the local PHU to discuss the exposure. They will assess:

Whether the exposure meets the definition of a “contact”
The time since exposure
The patient’s risk factors

If a contact is already symptomatic: Do not administer PEP. Test, isolate, and notify the PHU .

Managing a Measles Exposure in Your Practice

If a confirmed measles case attended your clinic while infectious, the risk of transmission to susceptible staff and patients is very high. Here is what you must do :

Immediate Steps

Identify all exposed individuals – anyone in the waiting room or clinical areas from the time the case entered until 30 minutes after they left
Compile a spreadsheet including:
- Full name
- Contact information (phone, email, address)
- Date of birth
- Any known high-risk status (pregnancy, immunocompromise)
Contact your local PHU immediately – they will guide the response

The PHU Will Coordinate

Assessment of which contacts require PEP
Supply and delivery of MMR vaccine and/or NHIG
Communication with contacts (you may be asked to administer PEP to contacts who attend your practice)

Documentation Requirements

Record all MMR administrations in the Australian Immunisation Register (AIR) – this is a legislative requirement
Report any adverse events following immunisation to the PHU
Notify the PHU of any patient who refuses PEP or in whom PEP administration fails

The “Born 1966 or Later” Rule

Anyone born during or after 1966 who does not have documented evidence of two MMR doses should be offered vaccination .

Why 1966? People born before 1966 are generally considered immune due to high measles circulation before widespread vaccination. However, if concerned, they can discuss serological testing with their GP .

Do You Need to Check Serology Before Vaccinating?

No. There is no need to check measles serology prior to vaccination . It is safe to administer MMR vaccine to a person who is already immune. Additional doses do not cause harm.

This is important because:

Serology delays vaccination
Serology is more expensive than vaccination
Many adults do not have reliable records of childhood vaccination

Infants Travelling Overseas: Updated ATAGI Advice

The Australian Technical Advisory Group on Immunisation (ATAGI) has strengthened its guidance for infants travelling overseas :

Recommendation: Infants aged 6 to 11 months should receive an additional dose of MMR vaccine before international travel.

Critical dosing schedule for these infants:

Dose 1 (early dose): 6–11 months (pre-travel)
Dose 2: 12 months of age or 4 weeks after dose 1 – whichever is later
Dose 3: 18 months (as MMRV, routinely scheduled)

If the early dose is given at >11 months but before 12 months: It does not need to be repeated. The infant still requires the routine 12-month and 18-month doses .

Contraindications to MMR

MMR is a live-attenuated vaccine and is not recommended for :

Pregnant women
Individuals with severe immunocompromise (e.g., haematological malignancies, high-dose immunosuppressive therapy)
History of anaphylaxis to a previous dose or vaccine component

Infection Control in Healthcare Settings

Protecting Your Staff

Healthcare workers are at increased occupational risk. All healthcare facilities should have an occupational vaccination program that offers measles immunity screening and vaccination to new and existing staff – including administrative and non-clinical staff .

Target: Two documented doses of MMR vaccine for all staff born during or after 1966.

Some jurisdictions are offering free adult catch-up MMR vaccination for healthcare workers. For example, Western Health in Victoria recently ran a campaign for staff aged 20–59 years with fewer than two documented doses .

After a Known Exposure in Your Facility

Identify all exposed staff (use roster and sign-in records)
Assess their immunity status (AIR record or documented vaccination history)
For non-immune staff:
- Offer MMR vaccine (within 72 hours of exposure if possible)
- Exclude from work from day 5 to day 21 after exposure if they remain unvaccinated
Notify the PHU

Laboratory Testing: What You Need to Know

Test Ordering

For suspected current infection :

Specimen	Test	Notes
Throat swab (dry or UTM)	PCR for measles	Preferred specimen
First-pass urine	PCR for measles	Collect ≥10-20 mL
Blood (serum)	Measles IgM & IgG	IgM may be negative early

Turnaround Times

PCR results: Varies by laboratory. Mark “URGENT” to expedite.
Serology: Typically 1–3 days

Notification Pathways

Laboratories are also required to notify PHUs of confirmed measles. However, do not rely on the laboratory to do this for you. Clinician notification is faster and allows public health action to begin immediately.

Pros and Cons of Current Outbreak Response Strategies

Pros

Highly effective vaccine: Two doses provide 99% protection against measles
Free vaccine for eligible groups: Reduces financial barriers
Clear notification pathways: Statutory requirements ensure rapid public health response
Established PEP protocols: MMR and NHIG options cover different risk groups
Strong surveillance system: National Notifiable Disease Surveillance System tracks cases

Cons

Gaps in adult vaccination records: Up to 50% of adults aged 20-59 in some areas lack documented evidence of two MMR doses
Delayed diagnosis in vaccinated individuals: Atypical presentations increase risk of missed diagnosis
Waiting room exposures continue to occur: Despite alerts, cases are still transmitting in GP waiting rooms
NHIG access requires PHU coordination: Cannot be administered empirically in primary care
Public complacency: Many patients do not perceive measles as a current threat

Frequently Asked Questions

Is measles still a notifiable disease in Australia?

Yes. Measles is a Group A notifiable disease in all jurisdictions. This means notification is required by telephone within hours of first suspicion – not after laboratory confirmation .

What is the PHU contact number?

The national contact number for Public Health Units is 1300 066 055 . This will connect you to the PHU in your state or territory.

Can I give MMR vaccine to a patient who is unsure of their vaccination history?

Yes. It is safe to administer MMR vaccine without checking serology. No harm comes from giving an additional dose to someone who is already immune .

What should I do if a measles case occurs in my waiting room?

Identify all exposed individuals (staff and patients)
Compile a spreadsheet with their contact details
Contact your local PHU immediately – they will coordinate the response

How long should a measles patient isolate?

Cases should be isolated from onset of symptoms until 4 days after the rash appears . They should not attend childcare, school, or work during this period.

Can pregnant women receive the MMR vaccine?

No. MMR is a live-attenuated vaccine and is contraindicated in pregnancy. Pregnant women who are exposed to measles should receive NHIG as post-exposure prophylaxis .

What is the treatment for measles?

There is no specific antiviral treatment for measles. Management is supportive – fever management, hydration, and monitoring for complications (pneumonia, otitis media, encephalitis) .

How many measles cases were there in Australia in 2025?

There were 180 notified cases of measles in Australia in 2025 – more than triple the 57 cases reported in 2024 .

Conclusion

The current measles outbreak in Australia is a wake-up call. Elimination does not mean immunity from importation. And importation, as we are now seeing, leads to local transmission when population immunity gaps exist.